Wednesday 21 September 2022

BridgeBio Pharma and Zydus US arm gets EU approval for NULIBRY

BridgeBio Pharma and Zydus US arm gets EU approval for NULIBRY
BridgeBio Pharma and Zydus US arm gets EU approval for NULIBRY

BridgeBio Pharma, Inc , a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd. announced the European Commission (EC) has granted marketing authorization for NULIBRY  (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A.

Pradip Mahajan Wed, 09/21/2022 - 15:25

source https://www.pharmatutor.org/pharma-news/2022/bridgebio-pharma-and-zydus-us-arm-gets-eu-approval-for-nulibry

No comments:

Post a Comment

Pharma openings

  Opportunity for M.Pharm, Msc or PhD as Scientist at PGIMER M.Pharmacy or M.Sc 6 Year of Research Experience or PhD with 3 year of Experien...